Fidelity Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-234,098
| Closed | -$712K | – | 5788 |
|
|
2024
Q4 | $712K | Buy |
234,098
+19,502
| +9% | +$84.9K | ﹤0.01% | 2790 |
|
|
2024
Q3 | $1.11M | Buy |
214,596
+47,768
| +29% | +$237K | ﹤0.01% | 2561 |
|
|
2024
Q2 | $429K | Buy |
166,828
+159,200
| +2,087% | +$544K | ﹤0.01% | 2786 |
|
|
2024
Q1 | $37.5K | Buy |
7,628
+5,796
| +316% | +$34.3K | ﹤0.01% | 3733 |
|
|
2023
Q4 | $16.1K | Sell |
1,832
-1,892,275
| -100% | -$15.5M | ﹤0.01% | 4052 |
|
|
2023
Q3 | $21.7M | Sell |
1,894,107
-61,808
| -3% | -$1.19M | ﹤0.01% | 1561 |
|
|
2023
Q2 | $49.5M | Buy |
1,955,915
+110,683
| +6% | +$3.45M | ﹤0.01% | 1279 |
|
|
2023
Q1 | $59.4M | Buy |
1,845,232
+35,977
| +2% | +$1.12M | 0.01% | 1193 |
|
|
2022
Q4 | $33.4M | Buy |
1,809,255
+60,265
| +3% | +$1.38M | ﹤0.01% | 1417 |
|
|
2022
Q3 | $47.2M | Buy |
1,748,990
+534,672
| +44% | +$10.8M | ﹤0.01% | 1263 |
|
|
2022
Q2 | $16.8M | Sell |
1,214,318
-17,512
| -1% | -$270K | ﹤0.01% | 1719 |
|
|
2022
Q1 | $24M | Buy |
1,231,830
+51,645
| +4% | +$783K | ﹤0.01% | 1706 |
|
|
2021
Q4 | $19.3M | Sell |
1,180,185
-1,510,971
| -56% | -$25.2M | ﹤0.01% | 1839 |
|
|
2021
Q3 | $75M | Sell |
2,691,156
-4,144
| -0.2% | -$118K | 0.01% | 1239 |
|
|
2021
Q2 | $79.9M | Sell |
2,695,300
-81,400
| -3% | -$2.35M | 0.01% | 1218 |
|
|
2021
Q1 | $77.6M | Sell |
2,776,700
-75,300
| -3% | -$2.08M | 0.01% | 1185 |
|
|
2020
Q4 | $80.8M | Buy |
2,852,000
+2,850,100
| +150,005% | +$73.8M | 0.01% | 1130 |
|
|
2020
Q3 | $48K | Sell |
1,900
-5,700
| -75% | -$149K | ﹤0.01% | 2894 |
|
|
2020
Q2 | $186K | Hold |
7,600
| – | – | ﹤0.01% | 2641 |
|
|
2020
Q1 | $112K | Sell |
7,600
-25
| -0.3% | -$517 | ﹤0.01% | 2660 |
|
|
2019
Q4 | $123K | Buy |
7,625
+7,600
| +30,400% | +$118K | ﹤0.01% | 2718 |
|
|
2019
Q3 | $0 | Sell |
25
-35,400
| -100% | -$433K | ﹤0.01% | 4302 |
|
|
2019
Q2 | $459K | Sell |
35,425
-28,900
| -45% | -$364K | ﹤0.01% | 2546 |
|
|
2019
Q1 | $1.01M | Sell |
64,325
-22,501
| -26% | -$390K | ﹤0.01% | 2416 |
|
|
2018
Q4 | $1.75M | Sell |
86,826
-263,204
| -75% | -$5.8M | ﹤0.01% | 2309 |
|
|
2018
Q3 | $8.7M | Buy |
350,030
+241,830
| +224% | +$6.58M | ﹤0.01% | 1972 |
|
|
2018
Q2 | $2.97M | Sell |
108,200
-137,436
| -56% | -$4.13M | ﹤0.01% | 2270 |
|
|
2018
Q1 | $7.57M | Buy |
245,636
+44,036
| +22% | +$1.42M | ﹤0.01% | 2033 |
|
|
2017
Q4 | $7.21M | Sell |
201,600
-47,600
| -19% | -$1.37M | ﹤0.01% | 2047 |
|
|
2017
Q3 | $6.87M | Sell |
249,200
-76,700
| -24% | -$1.86M | ﹤0.01% | 2071 |
|
|
2017
Q2 | $8.6M | Buy |
325,900
+9,000
| +3% | +$201K | ﹤0.01% | 1997 |
|
|
2017
Q1 | $6.59M | Buy |
316,900
+216,900
| +217% | +$4.46M | ﹤0.01% | 2105 |
|
|
2016
Q4 | $2.07M | Buy |
+100,000
| New | +$1.67M | ﹤0.01% | 2371 |
|
|
2016
Q1 | – | Sell |
-555,600
| Closed | -$19M | – | 2750 |
|
|
2015
Q4 | $19M | Buy |
+555,600
| New | +$19.3M | ﹤0.01% | 1708 |
|
|
2014
Q4 | – | Sell |
-1,029,800
| Closed | -$19.9M | – | 2854 |
|
|
2014
Q3 | $19.9M | Buy |
1,029,800
+26,100
| +3% | +$680K | ﹤0.01% | 1744 |
|
|
2014
Q2 | $34.1M | Buy |
1,003,700
+700,400
| +231% | +$21.9M | ﹤0.01% | 1536 |
|
|
2014
Q1 | $9.55M | Buy |
+303,300
| New | +$9.48M | ﹤0.01% | 2038 |
|
Other funds holding RVNC
Fidelity Investments's RVNC Position: Q1 2025 in Review
Fidelity Investments sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 234,098 shares — an estimated $712K sold.
Fidelity Investments first reported a position in RVNC in Q1 2014 and held it in 37 quarters. The position peaked at $80.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Fidelity Investments reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Fidelity Investments sold 234,098 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $712K.
- Fidelity Investments first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 37 quarters.
- Fidelity Investments's Revance Therapeutics, Inc. position peaked at $80.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.